This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ophthalmology, Other  • Alert me on articles by topic

Rong-Fang Wang, MD; Steven M. Podos, MD; Janet B Serle, MD; Thomas W. Mittag, PhD; F. Ventosa, MD; Bernard Becker, MD

Arch Ophthalmol. 2000;118:74-77.

Objective  To evaluate the possible additivity of the effects of latanoprost and 8-iso prostaglandin E₂ (8-iso PGE₂) on intraocular pressure (IOP) in monkey eyes with laser-induced glaucoma.

Methods  The IOP was measured hourly for 6 hours beginning at 9:30 AM on day 1 (baseline day), days 6 and 7 (single-agent therapy), and days 13 and 14 (combination therapy with both agents). Following 1 day of baseline measurement, 4 monkeys with unilateral glaucoma received monotherapy twice daily with either 1 drop of 0.005% latanoprost, or 0.1% 8-iso PGE₂, 25 µL, at 9:30 AM and 3:30 PM from days 2 through 7. From days 8 through 14, both agents were applied twice daily 5 minutes apart.

Results  The maximum reduction of IOP (mean ± SEM) was 8.8 ± 1.9 mm Hg (26%) (P<.05) with latanoprost alone and 6.5 ± 1.0 mm Hg (21%) (P<.01) with 8-iso PGE₂ alone, 2 hours after the morning dosing on day 7. A further reduction of IOP of 4.0 ± 0.6 mm Hg was produced when 8-iso PGE₂ was added to latanoprost and of 3.0 ± 0.7 mm Hg was produced when latanoprost was added to 8-iso PGE₂ on day 13 before the morning dosing. Combination therapy with both agents caused maximum IOP reductions from baseline of 11.3 ± 3.0 mm Hg (33%) (P<.05) (latanoprost with 8-iso PGE₂added) and of 9.8 ± 1.3 mm Hg (31%) (P<.01) (8-iso PGE₂ with latanoprost added) on day 14.

Conclusion  Latanoprost and 8-iso PGE₂ have an additive effect on IOP in glaucomatous monkey eyes.

Clinical Relevance  At least 50% of patients are treated with more than 1 ocular hypotensive medication. Thus, the determination of the additive effects on IOP of glaucoma medications will help to define optimum treatment regimens.

From the Department of Ophthalmology, Mount Sinai School of Medicine of New York University, New York (Drs Wang, Podos, Serle, and Mittag); La Asociacion Para Evitar La Ceguera En Mexico, IAP, Hospital Dr Luis Sanchez Bulens, San Lucas Coyoacan, Mexico, DF (Dr Ventosa); and the Department of Ophthalmology and Visual Science, Washington University Medical School, St Louis, Mo (Dr Becker). Dr Podos is a consultant to Alcon Laboratories, Inc, Ft Worth, Tex. Drs Podos, Mittag, and Becker have a proprietary interest in the drug evaluated in this article.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Effects of Prostaglandin Analogues on Prostanoid EP1, EP2, and EP3 Receptor-Deficient Mice.
Ota et al.
IOVS 2006;47:3395-3399.
ABSTRACT | FULL TEXT  

Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension.
Chiba et al.
Br. J. Ophthalmol. 2006;90:314-317.
ABSTRACT | FULL TEXT  

Additivity of Bimatoprost or Travoprost to Latanoprost in Glaucomatous Monkey Eyes
Gagliuso et al.
Arch Ophthalmol 2004;122:1342-1347.
ABSTRACT | FULL TEXT  

Aqueous Humor Dynamics in Monkeys after Topical 8-Iso PGE2
Gabelt et al.
IOVS 2004;45:892-899.
ABSTRACT | FULL TEXT